{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:50:11Z","timestamp":1790041811744,"version":"4.0.1"},"reference-count":41,"publisher":"Sociedade Brasileira de Pneumologia e Tisiologia","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Bras Pneumol."],"abstract":"<jats:p>Objective: Depression and anxiety have been documented in people with cystic fibrosis (CF), jeopardizing treatment adherence. To date, no studies have assessed the prevalence of psychosocial issues in adolescents with CF in Brazil. We sought to assess the prevalence of depression and anxiety in adolescents with CF in Brazil, as well as the impact of depression and anxiety on treatment adherence. Methods: This was a multicenter, prospective, observational, longitudinal study conducted between 2017 and 2019 at 14 CF referral centers in Brazil. We used standardized tools such as the nine-item Patient Health Questionnaire (for depression), the seven-item Generalized Anxiety Disorder scale (for anxiety), and the eight-item Morisky Medication Adherence Scale (for treatment adherence) in order to collect data on 218 CF patients at two different time points. Results: The prevalence of depression was 19.1% at time point 1 and 15.4% at time point 2. The prevalence of anxiety was 19.1% at time point 1 and 18.0% at time point 2. Depression and anxiety were significantly higher in female patients and lower in those who underwent home physiotherapy or had psychological support. Significant correlations were found between depression and anxiety at both time points, the associations being strongest at time point 1 (r = 0.68; p &lt; 0.001). Most (66.7%) of the study participants reported low adherence to treatment, and the remainder reported either average adherence (in 28%) or high adherence (in 5.3%). Depression and anxiety showed inverse correlations with treatment adherence. Conclusions: The prevalence of depression and anxiety in adolescents with CF in Brazil appears to be similar to that reported in other countries, being higher in females and lower in those undergoing home physiotherapy or receiving psychological care. Depression and anxiety appear to correlate with lower treatment adherence. Treating psychosocial issues may effectively improve rates of treatment adherence in adolescents with CF.<\/jats:p>","DOI":"10.36416\/1806-3756\/e20240416","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T15:11:33Z","timestamp":1748272293000},"page":"e20240416","source":"Crossref","is-referenced-by-count":3,"title":["Depression and anxiety in adolescents with cystic fibrosis in Brazil: prevalence, stability over time, and relationship with treatment adherence"],"prefix":"10.36416","author":[{"given":"Tatiana","family":"Rozov1","sequence":"first","affiliation":[{"name":"1. Universidade de S\u00e3o Paulo, S\u00e3o Paulo (SP) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Tadeu Nolasco da Silva2","sequence":"additional","affiliation":[{"name":"2. Universidade Estadual de Campinas, Campinas (SP) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"\u00c2ngela Gon\u00e7alves Oliveira Ribeiro2","sequence":"additional","affiliation":[{"name":"2. Universidade Estadual de Campinas, Campinas (SP) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neiva","family":"Damaceno3","sequence":"additional","affiliation":[{"name":"3. Irmandade da Santa Casa de Miseric\u00f3rdia de S\u00e3o Paulo, S\u00e3o Paulo (SP) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Angelica Pinheiro Santos Santana4","sequence":"additional","affiliation":[{"name":"4. Hospital Otavio Mangabeira, Salvador (BA) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Jose Cauduro Marostica5","sequence":"additional","affiliation":[{"name":"5. Universidade Federal do Rio Grande do Sul, Porto Alegre (RS) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"de C\u00e1ssia Nunes Cruz Melotti6","sequence":"additional","affiliation":[{"name":"6. Centro de Refer\u00eancia em Fibrose C\u00edstica do Esp\u00edrito Santo, Vit\u00f3ria (ES) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"de Carvalho Martins7","sequence":"additional","affiliation":[{"name":"7. Universidade Federal do Par\u00e1, Bel\u00e9m (PA) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Ant\u00f4nio Riedi8","sequence":"additional","affiliation":[{"name":"8. Universidade Federal do Paran\u00e1, Curitiba (PR) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edna","family":"Lucia Santos de Souza9","sequence":"additional","affiliation":[{"name":"9. Universidade Federal da Bahia, Salvador (BA) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norberto","family":"Ludwig Neto10","sequence":"additional","affiliation":[{"name":"10. Hospital Infantil Joana de Gusm\u00e3o, Florian\u00f3polis (SC) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Abensur Athanazio1","sequence":"additional","affiliation":[{"name":"1. Universidade de S\u00e3o Paulo, S\u00e3o Paulo (SP) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francyelly","family":"Wisnievski Yamamoto11","sequence":"additional","affiliation":[{"name":"11. Universidade Estadual Paulista, Botucatu (SP) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lusmaia","family":"Damaceno Camargo Costa12","sequence":"additional","affiliation":[{"name":"12. Universidade Federal de Goi\u00e1s, Goi\u00e2nia (GO) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Mayumi Chiba13","sequence":"additional","affiliation":[{"name":"13. Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo (SP) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela","family":"Sad14","sequence":"additional","affiliation":[{"name":"14. Instituto Fernandes Figueira, Rio de Janeiro (RJ) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Dirceu Ribeiro2","sequence":"additional","affiliation":[{"name":"2. Universidade Estadual de Campinas, Campinas (SP) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"L. Quittner15","sequence":"additional","affiliation":[{"name":"15. Joe DiMaggio Cystic Fibrosis, Pulmonary & Sleep Center, Holywood (FL) USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brazilian","family":"Anxiety, Depression and Adherence Study Group (BADAS)1","sequence":"additional","affiliation":[{"name":"1. Universidade de S\u00e3o Paulo, S\u00e3o Paulo (SP) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22288","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1.           Lord L, McKernon D, Grzeskowiak L, Kirsa S, Ilomaki J. Depression and anxiety prevalence in people with cystic fbrosis and their caregivers: a systematic review and meta analysis. Soc Psychiatry Psychiat Epidemiol. 2023;58(2):287-298 https:\/\/doi.org\/10.1007\/s00127-022-02307-w","DOI":"10.1007\/s00127-022-02307-w"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2.           Guta MT, Tekalign T, Awoke N, Fite RO, Dendir G, Lenjebo TL. Global Burden of Anxiety and Depression among Cystic Fibrosis Patient: Systematic Review and Meta-Analysis. Int J Chronic Dis. 2021;2021:6708865. https:\/\/doi.org\/10.1155\/2021\/6708865","DOI":"10.1155\/2021\/6708865"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3.           Quittner AL, Goldbeck L, Abbott J, Duff A, Lambrecht P, Sol\u00e9 A, et al. Prevalence of depression and anxiety in patients with cystic ?brosis and parent caregivers: results of The International Depression Epidemiological Study across nine countries. Thorax. 2014;69(12):1090-1097. https:\/\/doi.org\/10.1136\/thoraxjnl-2014-205983","DOI":"10.1136\/thoraxjnl-2014-205983"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4.           Gundogdu U, Fis NP, Eralp EE, Karadag BT. Major depression and psychiatric comorbidity in Turkish children and adolescents with cystic fibrosis. Pediatr Pulmonol. 2019;54(12):1927-1935. https:\/\/doi.org\/10.1002\/ppul.24492","DOI":"10.1002\/ppul.24492"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5.           Graziano S, Span\u00f2 B, Majo F, Righelli D, Vincenzina L, Quittner A, et al. Rates of depression and anxiety in Italian patients with cystic fibrosis and parent caregivers: Implementation of the Mental Health Guidelines. Respir Med. 2020;172:106147. https:\/\/doi.org\/10.1016\/j.rmed.2020.106147","DOI":"10.1016\/j.rmed.2020.106147"},{"key":"ref5","unstructured":"6.           Grupo Brasileiro de Estudos de Fibrose C\u00edstica (GBEFC) [homepage on the Internet]. Curitiba: GBEFC; c2024 [cited 2024 Dec 1]. The Brazilian Cystic Fibrosis Registry Report 2017. [Adobe Acrobat document, 56p.]. Available from: http:\/\/portalgbefc.org.br\/ckfinder\/userfiles\/files\/REBRAFC_2017_EN.pdf"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7.           Frederick C. Psychosocial Challenges\/Transition to Adulthood. Pediatr Clin North Am. 2016;63(4):735-749. https:\/\/doi.org\/10.1016\/j.pcl.2016.04.011","DOI":"10.1016\/j.pcl.2016.04.011"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8.           Pfeffer PE, Pfeffer JM, Hodson ME. The psychosocial and psychiatric side of cystic fibrosis in adolescents and adults. J Cyst Fibros. 2003;2(2):61-68. https:\/\/doi.org\/10.1016\/S1569-1993(03)00020-1","DOI":"10.1016\/s1569-1993(03)00020-1"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9.           Tluczek A, Laxova A, Grieve A, Heun A, Brown RL, Rock MJ, et al. Long-term follow-up of cystic fibrosis newborn screening: psychosocial functioning of adolescents and young adults. J Cyst Fibros. 2014;13(2):227-234. https:\/\/doi.org\/10.1016\/j.jcf.2013.10.001","DOI":"10.1016\/j.jcf.2013.10.001"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10.        Forti-Buratti MA, Saikia R, Wilkinson EL, Ramchandani PG. Psychological treatments for depression in pre-adolescent children (12 years and younger): systematic review and meta-analysis of randomised controlled trials. Eur Child Adolesc Psychiatry. 2016;25(10):1045-1054. https:\/\/doi.org\/10.1007\/s00787-016-0834-5","DOI":"10.1007\/s00787-016-0834-5"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11.        Quittner AL, Abbott J, Georgiopoulos AM, Goldbeck L, Smith B, Hempstead SE, et al. International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety. Thorax. 2016;71(1):26-34. https:\/\/doi.org\/10.1136\/thoraxjnl-2015-207488","DOI":"10.1136\/thoraxjnl-2015-207488"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12.        Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen F, et al. - ECFS best practice guidelines: the 2018 revision - J Cyst Fibros. 2018;17(2):153-178. https:\/\/doi.org\/10.1016\/j.jcf.2018.02.006","DOI":"10.1016\/j.jcf.2018.02.006"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13.        Verkleij M, Georgiopoulos AM, Friedman D. Development and evaluation of an internet-based cognitive behavioral therapy intervention for anxiety and depression in adults with cystic fibrosis (eHealth CF-CBT): An international collaboration. Internet Interv. 2021;24:100372.72. https:\/\/doi.org\/10.1016\/j.invent.2021.100372","DOI":"10.1016\/j.invent.2021.100372"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14.        Verkleij M, Georgiopoulos AM, Barendrecht H, Friedman D. Pilot of a therapist-guided digital mental health intervention (eHealth CF-CBT) for adults with cystic fibrosis. Pediatr Pulmonol. 2023;58(7):2094-2103. https:\/\/doi.org\/10.1002\/ppul.26438","DOI":"10.1002\/ppul.26438"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15.        Friedman D, Smith BA, Bruce A, Schwartz CE, Lee H, Pinsky H, et al. Feasibility and acceptability of a CF-specific cognitive-behavioral preventive intervention for adults integrated into team-based care. Pediatr Pulmonol. 2022;57(11):2781-2790. https:\/\/doi.org\/10.1002\/ppul.26101","DOI":"10.1002\/ppul.26101"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16.        Friedman D, Smith B, Sher Y, Bruce A, He J, Kim J, et al. 463 Outcomes of a randomized controlled trial of cystic fibrosis-cognitive behavioral therapy in adults with cystic fibrosis with mild depression and anxiety. J Cyst Fibros. 2023,22:S243-S244. https:\/\/doi.org\/10.1016\/S1569-1993(23)01388-7","DOI":"10.1016\/s1569-1993(23)01388-7"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17.        Spitzer RL, Kroenke F, Willians JBW. Validation and utility of a self-report version of PRIME-MD. The OHQ primary care study. JAMA 1999;(18):1734-1744. https:\/\/doi.org\/10.1001\/jama.282.18.1737","DOI":"10.1001\/jama.282.18.1737"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18.        Kroenke K, Spitzer RL, Willians JBW. The PHQ-9 Validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-613. https:\/\/doi.org\/10.1046\/j.1525-1497.2001.016009606.x","DOI":"10.1046\/j.1525-1497.2001.016009606.x"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19.        Spitzer LR, Kroenke K, Williams JB, L\u00f6we B. A Brief Measure for Assessing Generalized Anxiety Disorder. Arch Intern Med. 2006;166(10):1092-1097. https:\/\/doi.org\/10.1001\/archinte.166.10.1092","DOI":"10.1001\/archinte.166.10.1092"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20.        Morisk DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67-74. https:\/\/doi.org\/10.1097\/00005650-198601000-00007","DOI":"10.1097\/00005650-198601000-00007"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21.        Os\u00f3rio FL, Crippa JA, Loureiro SR. Study of the psychometric qualities of the Brief Social Phobia Scale (BSPS) in Brazilian university students. Eur Psychiatry. 2010;25(3):178-188. https:\/\/doi.org\/10.1016\/j.eurpsy.2009.08.002","DOI":"10.1016\/j.eurpsy.2009.08.002"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22.        de Oliveira-Filho AD, Morisky DE, Neves SJ, Costa FA, de Lyra DP Jr. The 8-item Morisky Medication Adherence Scale: validation of a Brazilian-Portuguese version in hypertensive adults. Res Social Adm Pharm. 2014;10(3):554-561. https:\/\/doi.org\/10.1016\/j.sapharm.2013.10.006","DOI":"10.1016\/j.sapharm.2013.10.006"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"23.        Athanazio RA, Silva Filho LVRF, Vergara AA, Ribeiro AF, Riedi CA, Procianoy EDFA, et al . Brazilian guidelines for the diagnosis and treatment of cystic fibrosis. J Bras Pneumol. 2017;43(3):219-245. https:\/\/doi.org\/10.1590\/s1806-37562017000000065","DOI":"10.1590\/s1806-37562017000000065"},{"key":"#cr-split#-ref23.1","unstructured":"24. World Health Organization [homepage on the Internet]. Geneva: World Health Organization [updated 2017 Jan 3"},{"key":"#cr-split#-ref23.2","unstructured":"cited 2024 Dec 1]. Depression and Other Common Mental Disorders. Global Health Estimates. Available from: https:\/\/www.who.int\/publications\/i\/item\/depression-global-health-estimates"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25.        Quittner AL, Zhang J, Marynchenko M, Chopra P, Signorovitch J, Yushkina Y, et al. Pulmonary medication adherence and health-care use in cystic fibrosis. Chest. 2014;146(1):142-151. https:\/\/doi.org\/10.1378\/chest.13-1926","DOI":"10.1378\/chest.13-1926"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26.        Barker DH, Quittner AL. Parental depression and pancreatic enzyme adherence in children with cystic fibrosis. Pediatrics. 2016;137(2):e20152296. https:\/\/doi.org\/10.1542\/peds.2015-2296","DOI":"10.1542\/peds.2015-2296"},{"key":"ref26","unstructured":"27.        Waters I, Floffert G, Valsemis J. CF Care Guidelines for Screening and Treating Depression and Anxiety, 1-26 April 2018. Available from: https:\/\/www2.gov.bc.ca\/assets\/gov\/health\/practitioner-pro\/bc-guidelines\/cystic-fibrosis\/cf_care_guidelines_for_screening_and_treating_depression_and_anxiety.pdf"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28.        Modi AC, Driscoll KA, Montag-Leifling K, Acton JD. Screening for symptoms of depression and anxiety in adolescents and young adults with CF. Pediatr Pulmonol. 2011;46(2):153-9. https:\/\/doi.org\/10.1002\/ppul.21334","DOI":"10.1002\/ppul.21334"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29.        Schechter MS, Obstrenga JS, Fink AK, Barker DH, Sawicki GS, Quittner AL. Decreased survival in cystic fibrosis patients with a positive screen for depression. J Cyst Fibros. 2021;20(1):120-126. https:\/\/doi.org\/10.1016\/j.jcf.2020.07.020","DOI":"10.1016\/j.jcf.2020.07.020"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30.        Talwalkar JS, Koff JL, Lee HB, Britto CJ, Mulenos AM, Georgiopoulos AM. Cystic Fibrosis Transmembrane Regulator Modulators: Implications for the Management of Depression and Anxiety in Cystic Fibrosis. Psychosomatics. 2017;58(4):343-354. https:\/\/doi.org\/10.1016\/j.psym.2017.04.001","DOI":"10.1016\/j.psym.2017.04.001"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"31.        Heo S, Young DC, Safirstein J, Bourque B, Antell MH, Diloreto S, et al. Mental status changes during elexacaftor\/tezacaftor \/ ivacaftor therapy. J Cyst Fibros. 2022;21(2):339-343. https:\/\/doi.org\/10.1016\/j.jcf.2021.10.002","DOI":"10.1016\/j.jcf.2021.10.002"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32.        Graziano S, Boldrini F, Pellicano GR, Milo F, Majo F, Cristiani L, et al. Longitudinal Effects of Elexacaftor\/Tezacaftor\/Ivacaftor: Multidimensional Assessment of Neuropsychological Side Effects and Physical and Mental Health Outcomes in Adolescents and Adults. Chest. 2024;165(4):800-809. https:\/\/doi.org\/10.1016\/j.chest.2023.10.043","DOI":"10.1016\/j.chest.2023.10.043"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33.        Baroud E, Chaudhary N, Georgiopoulos AM. Management of neuropsychiatric symptoms in adults treated with elexacaftor\/tezacaftor\/ivacaftor. Pediatr Pulmonol. 2023;58(7):1920-1930. https:\/\/doi.org\/10.1002\/ppul.26412","DOI":"10.1002\/ppul.26412"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"34.        Lee TWR, Duff AJA. Questions and Answers? Depression Symptoms Associated with Elexacaftor\/Tezacaftor\/Ivacaftor Treatment for Cystic Fibrosis. Am J Respir Crit Care Med. 2024;209(3):239-241. https:\/\/doi.org\/10.1164\/rccm.202311-2159ED","DOI":"10.1164\/rccm.202311-2159ed"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"35.        Sakon C, Vogt H, Brown CD, Tillman EM. A survey assessing the impact of COVID-19 and elexacaftor\/tezacaftor\/ifavacaftor on both physical and mental health in adults with cystic fibrosis. Pediatr Pulmonol. 2023;58(3):662-664. https:\/\/doi.org\/10.1002\/ppul.26260","DOI":"10.1002\/ppul.26260"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"36.        Bathgate CJ, Muther E, Georgiopoulos AM, Smith B, Tillman L, Graziano S, et al. Positive and negative impacts of elexacaftor\/tezacaftor\/ivacaftor: Healthcare providers' observations across US centers. Pediatr Pulmonol. 2023;58(9):2469-2477. https:\/\/doi.org\/10.1002\/ppul.26527","DOI":"10.1002\/ppul.26527"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"37.        Smith BA, Georgiopoulos AM, Mueller A, Abbott J, Lomas P, Aliaj E, et al. Impact of COVID -19 on mental health: effects on screening, care delivery, and people with cystic fibrosis. Journal of Cystic Fibrosis J Cyst Fibros. 2021;20 Suppl 3:31-38. https:\/\/doi.org\/10.1016\/j.jcf.2021.08.027","DOI":"10.1016\/j.jcf.2021.08.027"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"38.        Ramsey B, Correll CU, DeMaso DR, McKone E, Tullis E, Taylor-Cousar JL, et al. Elexacaftor\/Tezacaftor\/Ivacaftor Treatment and Depression-related Events. Am Am J Respir Crit Care Med. 2024;209(3):299-306. https:\/\/doi.org\/10.1164\/rccm.202308-1525OC","DOI":"10.1164\/rccm.202308-1525oc"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"39.        Papadakis L, Stander T, Mombourquette J, Richards CJ, Yonker LM, Lawton B, et al. Heterogeneity in Reported Side Effects Following Initiation of Elexacaftor-Tezacaftor-Ivacaftor: Experiences at a Quaternary CF Care Center. Pediatr Pulmonol. 2025;60(1):e27382. https:\/\/doi.org\/10.1002\/ppul.27382","DOI":"10.1002\/ppul.27382"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"40.        Landau EC, Verkleij M, Graziano S, Quittner AL, Georgiopoulos AM, Smith BA, et al Mental health screening in Cystic Fibrosis as an intervention: Patient and caregiver feedback on improving these processes. Respir Med. 2022;202:106955. https:\/\/doi.org\/10.1016\/j.rmed.2022.106955","DOI":"10.1016\/j.rmed.2022.106955"}],"container-title":["Jornal Brasileiro de Pneumologia"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T15:11:35Z","timestamp":1748272295000},"score":1,"resource":{"primary":{"URL":"https:\/\/jornaldepneumologia.com.br\/details\/4096\/en-US"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":41,"URL":"https:\/\/doi.org\/10.36416\/1806-3756\/e20240416","relation":{},"ISSN":["1806-3756"],"issn-type":[{"value":"1806-3756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]}}}